| abstract |
A prophylactic or therapeutic agent for spinal muscular atrophy according to the present invention includes a compound represented by formula (I) or a salt thereof: [Chemical formula 1] (I) wherein: W1, W2 and W3 are each selected regardless of the group consisting of C R2, C R3, C Rc and C Rd, and are defined by one of the following (i) to (iv): (i) when W3 is C R2, then W1 is C R3, W2 is C Rc or N, and R1 is a hydrogen atom; (ii) when W3 is C R3, then W1 is C R2, W2 is C Rc or N, and R1 is a hydrogen atom, C1-8 alkyl or C1-8 alkoxy; (iii) when W1 is C R2, then W2 is C Rc or N, W3 is C Rd, and R1 is an aliphatic heterocycle containing one or more nitrogen atoms, where the aliphatic heterocycle is optionally substituted with a non-aromatic substituent; and (iv) when W2 is C R2, W1 is C Rc, W3 is C Rd, and R1 is an aliphatic heterocycle containing one or more nitrogen atoms, where the aliphatic heterocycle is optionally substituted with a non-aromatic substituent; R2 is a 6 or more membered aromatic ring optionally substituted with a non-aromatic substituent; R3 is an aliphatic heterocycle containing one or more nitrogen atoms, where the aliphatic heterocycle is optionally substituted with a non-aromatic substituent; Q1 is selected from C Ra and N; Q2 is selected from C Rb and N; and Ra, Rb, Rc, and Rd are each independently selected from the group consisting of a hydrogen atom, halogen, C1-8 alkyl, C1-8 alkoxy, and a cyano group. |